Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVW-1001 Ophthalmic Eyelid Wipe Dosing Techniques in Dry Eye Disease
NCT07140380Phase 2Completed
- Sponsor
- IVIEW Therapeutics Inc.
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IVW-1001 in dry eye disease (DED) (3 arms), sponsored by IVIEW Therapeutics Inc. Primary endpoint: Tear production at Day 8. Started Aug 2025; status: completed.
02
Drugs
IVW-1001
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07140380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140380.